Previous 10 | Next 10 |
(NDC 51672-4131-1) Lot # 331771 (Expiration June 2021) Due to Cross-Contamination With Enalapril Maleate Taro Pharmaceuticals U.S.A., Inc. (“Taro” or the “Company”) is voluntarily recalling one (1) lot of Lamotrigine 100 mg Tablets, Lot # 331771 (expir...
Taro Pharmaceutical Industries Ltd. (NYSE:TARO) (“Taro” or the “Company”) today announced the final results of its modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares, nominal (par) value NIS 0.0001 p...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today announced the preliminary results of its modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares, nominal (par) value NIS 0...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has accepted the resignation of its Chief Financial Officer, Mariano Balaguer, effective January 3, 2020. Mr. Balaguer is leaving to accept the position of CFO at ano...
The FDA has granted tentative approval to Taro Pharmaceutical Industries' (NYSE: TARO ) tavaborole, the generic active ingredient in Kerydin (by Novartis (NYSE: NVS ) and Pfizer (NYSE: PFE )). More news on: Taro Pharmaceutical Industries Ltd., Novartis AG, Pfizer Inc., Healthcare stocks ...
Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) announced today that it has commenced a modified “Dutch auction” tender offer to repurchase up to $225 million in value of its ordinary shares at a price not greater than $92.0...
Image source: The Motley Fool. Taro Pharmaceutical Industries (NYSE: TARO) Q2 2019 Earnings Call Nov 05, 2019 , 8:00 a.m. ET Operator Continue reading
Taro Pharmaceutical Industries Ltd. (TARO) Q2 2020 Earnings Conference Call November 05, 2019 8:00 AM ET Company Participants William Coote - Assistant Vice President of Business Finance & Investor relations & Treasurer Dilip Shanghvi - Chairman of the Board of Directors ...
Taro Pharmaceutical (NYSE: TARO ): Q3 GAAP EPS of $1.46 misses by $0.26 . More news on: Taro Pharmaceutical Industries Ltd., Earnings news and commentary, Healthcare stocks news, Read more ...
Board of Directors Approves $300 Million Share Repurchase Program Taro Pharmaceutical Industries Ltd. (NYSE: TARO) (“Taro” or the “Company”) today provided unaudited financial results for the three and six months ended September 30, 2019. Quarter ended ...
News, Short Squeeze, Breakout and More Instantly...
Taro Pharmaceutical Industries Ltd. Company Name:
TARO Stock Symbol:
NYSE Market:
Taro Pharmaceutical Industries Ltd. Website:
2024-06-03 08:00:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-05-24 09:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Taro Shareholders Approve Merger with Sun Pharma Canada NewsWire MUMBAI, India and NEW YORK , May 23, 2024 /CNW/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiar...